Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DTC guidance comment extension

This article was originally published in The Gray Sheet

Executive Summary

Stakeholders have until Aug. 10 to submit comments on FDA's February direct-to-consumer advertising guidances (1"The Gray Sheet" Feb. 9, 2004, p. 6). The comment period had closed May 10, but FDA opted to reopen it after receiving "numerous requests" for more time, including a plea from AdvaMed and a memo from FDA's Division of Drug Marketing, Advertising & Communications on behalf of the drug industry...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT020346

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel